Recurrence of Renal Cell Cancer After Renal Transplantation in a Multicenter French Cohort

Cognard, Noëlle; Anglicheau, Dany; Gatault, Philippe; Girerd, Sophie; Essig, Marie; Ligny, Bruno Hurault de; Meur, Yann Le; Roy, F. Le; Garrouste, Cyril; Thierry, Antoine; Colosio, Charlotte; Rivalan, Joseph; Sayegh, Johnny; Choukroun, Gabriel; Moulin, Anne‐Marie; Caillard, Sophie

doi:10.1097/tp.0000000000002009

Cited by 22 publications

(22 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Twenty-one articles were case reports and three articles were not in English. Thus, 22 cohort studies [11,12,13,14,15,16,17,18,19,20,23,28,29,30,31,32,33,34,35,36,38,39] with a total of 320,190 KTx patients were enrolled. The literature retrieval, review, and selection process are demonstrated in Figure 1.…”

Section: Resultsmentioning

confidence: 99%

“…Despite screening for RCC among KTx candidates, de novo RCC has been reported among KTx patients in both native kidneys [11,12,13,14,15,16,17,18], and transplanted kidneys [17,19,20]. However, the incidence and incidence trends of RCC among KTx patients remain unclear [11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Incidence and Mortality of Renal Cell Carcinoma after Kidney Transplantation: A Meta-Analysis

Chewcharat

Thongprayoon

Bathini

et al. 2019

JCM

View full text Add to dashboard Cite

Background: The incidence and mortality of renal cell carcinoma (RCC) after kidney transplantation (KTx) remain unclear. This study's aims were (1) to investigate the pooled incidence/incidence trends, and (2) to assess the mortality/mortality trends in KTx patients with RCC. Methods: A literature search was conducted using the MEDLINE, EMBASE and Cochrane databases from inception through October 2018. Studies that reported the incidence or mortality of RCC among kidney transplant recipients were included. The pooled incidence and 95% CI were calculated using a random-effect model. The protocol for this meta-analysis is registered with PROSPERO; no. CRD42018108994. Results: A total of 22 observational studies with a total of 320,190 KTx patients were enrolled. Overall, the pooled estimated incidence of RCC after KTx was 0.7% (95% CI: 0.5–0.8%, I2 = 93%). While the pooled estimated incidence of de novo RCC in the native kidney was 0.7% (95% CI: 0.6–0.9%, I2 = 88%), the pooled estimated incidence of RCC in the allograft kidney was 0.2% (95% CI: 0.1–0.4%, I2 = 64%). The pooled estimated mortality rate in KTx recipients with RCC was 15.0% (95% CI: 7.4–28.1%, I2 = 80%) at a mean follow-up time of 42 months after RCC diagnosis. While meta-regression analysis showed a significant negative correlation between year of study and incidence of de novo RCC post-KTx (slopes = −0.05, P = 0.01), there were no significant correlations between the year of study and mortality of patients with RCC (P = 0.50). Egger's regression asymmetry test was performed and showed no publication bias in all analyses. Conclusions: The overall estimated incidence of RCC after KTX was 0.7%. Although there has been a potential decrease in the incidence of RCC post-KTx, mortality in KTx patients with RCC has not decreased over time.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Incidence and Mortality of Renal Cell Carcinoma after Kidney Transplantation: A Meta-Analysis

Chewcharat

Thongprayoon

Bathini

et al. 2019

JCM

View full text Add to dashboard Cite

show abstract

“…Because of immunosuppressive drugs use, the incidence of malignancies has increased significantly after renal transplantation. [4] It is generally believed that there are 3 main sources of tumor after renal transplantation: primary tumor after renal transplantation; tumor recurrence before renal transplantation; tumor derived from donor kidney. Urinary tract tumor especially urothelial carcinoma, is the main type of tumor after renal transplantation.…”

Section: Discussionmentioning

confidence: 99%

Primary small cell carcinoma after renal transplant

Wang

Wang²,

Liang³

et al. 2018

Medicine

View full text Add to dashboard Cite

Introduction:Primary small cell carcinoma (SCC) after renal transplantation is very rare. Here, we reported 1 case of primary SCC after renal transplantation and analyzed its clinical and pathological characteristics.Case presentation:A 55-year-old female underwent renal transplantation in our hospital 2 years ago and had been using tacrolimus for immunosuppressive therapy. Because of abdominal distention, the patient was admitted to our hospital. Computed tomography (CT) showed a malignant tumor of left kidney. Patient underwent surgical treatment and radical nephrectomy and lymph node dissection were selected. Postoperative pathological diagnosis was primary renal parenchyma and ureteral SCC. The patient has been treated with combination chemotherapy of lowpol (100 mg per day) and etoposide (10 mg per day). His vital signs are stable now, and he is receiving further treatment in our hospital.Conclusion:Because of immunosuppressive drugs use, the incidence of malignancies has increased significantly after renal transplantation. This case highlights the difficulty of diagnosis of primary SCC and the necessity of checking for neuroendocrine tumor after organ transplantation.

show abstract

“…The increased mortality may be explained by an increased incidence of RCC and metastatic RCC in these patients. In a study of 15 kidney transplant centers in France, the incidence of recurrent RCC after kidney transplant was 9.1% and the 5‐year survival of these patients was 41.7% 36 as compared to 91.4% in kidney transplant population without RCC 37 . In a meta‐analysis of 11 studies, the mortality rate in kidney transplant recipients with RCC was 15.0% at a mean follow‐up of 42 months after RCC diagnosis 38 .…”

Section: Prognosis Of Kidney Transplant Recipients With Cancermentioning

confidence: 99%

When ESKD complicates cancer screening and cancer treatment

Yasin

Holley

2020

Seminars in Dialysis

View full text Add to dashboard Cite

End-stage kidney disease (ESKD) affects the recommended screening, incidence, treatment, and mortality of cancer. Cancer occurring in a patient with ESKD can influence candidacy for kidney transplantation as well as dialysis decision-making and cancer treatment. Certain cancers are more common among ESKD patients, notably, viral-mediated cancers that are associated with human papilloma or hepatitis viruses, and urothelial cancers associated with analgesic and Balkan nephropathies. Solid tumors are not believed to occur more frequently in ESKD patients. The presence of ESKD may confer a higher risk of post-surgical complications as well as mortality. The cost-effectiveness of cancer screening depends upon individual cancer risk and estimated overall survival. The high mortality associated with ESKD argues against routine cancer screening in dialysis patients. Cancer treatment in ESKD may be complicated by the need to avoid, adjust doses of and/or coordinate the timing of administration of imaging contrast, chemotherapy, and immunotherapy with dialysis treatments. There is a general dearth of information on the treatment of cancer in ESKD patients. These issues will be discussed, and some general guidelines presented based upon the current literature.

show abstract

Recurrence of Renal Cell Cancer After Renal Transplantation in a Multicenter French Cohort

Abstract: Recurrences of clear cell RCC are not uncommon after kidney transplantation and are associated with very poor prognoses. These results should be considered before listing patients with a history of renal cancer for transplantation.

Cited by 22 publications

References 39 publications

Incidence and Mortality of Renal Cell Carcinoma after Kidney Transplantation: A Meta-Analysis

Incidence and Mortality of Renal Cell Carcinoma after Kidney Transplantation: A Meta-Analysis

Primary small cell carcinoma after renal transplant

When ESKD complicates cancer screening and cancer treatment

Contact Info

Product

Resources

About